4,4'-(1-ethyl-2-methyl-ethane-1,2-diyl)-bis-piperazine-2,6-dione | 906438-58-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4,4'-(1-ethyl-2-methyl-ethane-1,2-diyl)-bis-piperazine-2,6-dione
• 英文别名: dl-threo-2,3-bis(3,5-dioxopiperazin-1-yl)-pentane；4-[3-(3,5-Dioxopiperazin-1-yl)pentan-2-yl]piperazine-2,6-dione
• CAS: 906438-58-2
• 化学式: C₁₃H₂₀N₄O₄
• 分子量: 296.326
• InChiKey: WEMJBSKVBVVFQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  98.8
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Pharmaceutical compositions
  申请人：BRITISH TECHNOLOGY GROUP LIMITED

  公开号：EP0409499A2

  公开（公告）日：1991-01-23

  Compounds of formula II: wherein n is 0, 1 or 2, R₁, R₂, R₃ and R₄ are each separately selected from hydrogen, unsubstituted acyclic aliphatic hydrocarbon groups having a maximum of six carbon atoms and C₁₋₆ alkyl groups substituted by a hydroxy group or a C₁₋₆ alkoxy group, or one of R₁ and R₂ and one of R₃ and R₄ is hydrogen and the others are a trimethylene, tetramethylene or pentamethylene bridging group, and R₅ as hydrogen or an unsubstituted acyclic aliphatic hydrocarbon group having a maximum of six carbon atoms, but with the provisos that (a) when n is 0 the combinations R₁ = R₂ = R₃ = R₄ = R₅ = H and R₁ = R₂ = R₃ = R₅ = H, R₄ = methyl are excluded, and (b) when n is 0, R₁, R₃ and R₅ are each hydrogen, and each of R₂ and R₄ is other than hydrogen the compound is in other than the meso or erythro configuration, or a salt thereof formed with a physiologically acceptable inorganic or organic acid, are of use in therapy, particularly as cardioprotective agents.

  式 II.的化合物 其中 n 为 0、1 或 2，R₁、R₂、R₃ 和 R₄ 分别选自氢、最多具有 6 个碳原子的未取代无环脂肪族烃基和被羟基或 C₁₋₆ 烷氧基取代的 C₁₋₆ 烷基、或 R₁ 和 R₂ 中的一个以及 R₃ 和 R₄ 中的一个为氢，其它为三亚甲基、四亚甲基或五亚甲基桥基，且 R₅ 为氢或最多有六个碳原子的未取代的无环脂族烃基、但有以下但书：(a)当 n 为 0 时，不包括 R₁ = R₂ = R₃ = R₄ = R₅ = H 和 R₁ = R₂ = R₃ = R₅ = H、R₄ = 甲基的组合，以及(b)当 n 为 0 时，R₁、R₃ 和 R₅ 均为氢、(c) 当 n 为 0 时，R₁、R₃ 和 R 各为氢，且 R₂ 和 R₄ 中的每一个都不是氢，则该化合物处于中或红外构型之外，或其与生理上可接受的无机酸或有机酸形成的盐可用于治疗，特别是作为心脏保护剂。
• DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME
  申请人：Tosk, Inc.

  公开号：EP2242360B1

  公开（公告）日：2015-04-08
• JP2011524851A
  申请人：——

  公开号：JP2011524851A

  公开（公告）日：2011-09-08
• Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same
  申请人：Garland William A.

  公开号：US20120329744A1

  公开（公告）日：2012-12-27

  Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions.
• US8227517B2
  申请人：——

  公开号：US8227517B2

  公开（公告）日：2012-07-24